MY 1Alternative Names: CCRIS 4212; MS-5101; My-1; Mycobacterium bovis bcg extract; Selfenon
Latest Information Update: 22 Jan 2007
At a glance
- Originator Nihon Schering
- Class Antineoplastics
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer; Lymphoma; Malignant melanoma
Most Recent Events
- 22 Jan 2007 Discontinued - Preregistration for Lymphoma in Japan (Injection)
- 22 Jan 2007 Discontinued - Preregistration for Malignant melanoma in Japan (Injection)
- 22 Jan 2007 Discontinued - Preregistration for Cancer in Japan (Injection)